CQN-WA-SPIE
In the bulleted section of the release dated June 2, 2021, all of the references to June should be July.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005138/en/
The updated release reads:
RIT AND SPIE PARTNER ON 2021 PHOTONICS FOR QUANTUM EVENT
The program, now in its third year, focuses on how photonic devices are impacting quantum science, technology, and applications
On 12-16 July, SPIE, the international society for optics and photonics, and Rochester Institute of Technology (RIT), will present the 2021 Photonics for Quantum Digital Forum . Previously an RIT initiative, this year marks a new iteration of this event in the form of a partnership between RIT and SPIE.
The five-day event will include more than 20 speakers from across international industry and research as well as an interactive poster session. Discussions and presentations will focus on quantum topics spanning applications, experiments, quantum photonic integrated circuits, materials, integration between dissimilar material systems, devices, and concepts to support a national quantum foundry.
Invited speakers include Qunnect’s Noel Goddard ; the US Air Force Research Laboratory’s Michael Fanto ; Imperial College London’s Ian A. Walmsley ; Eleni Diamanti of Sorbonne University’s Laboratoire d'Informatique de Paris 6; Laboratoire Matériaux et Phénomènes Quantiques’ Sara Ducci ; the University of Birmingham’s Kai Bongs ; and Anton Zeilinger of the University of Vienna and the Institute for Quantum Optics and Quantum Information of the Austrian Academy of sciences.
The Photonics for Quantum program sessions include:
- 12 July: Networks and Communication
- 13 July: Computing and Simulation
- 14 July: Sensing and Imaging
- 15 July: Components
- 16 July: Special events and panels, including Women in Quantum (in conjunction with the SPIE Women in Optics program), global government initiatives and funding, and workforce and education
“RIT is thrilled to partner with SPIE to present this year’s Photonics for Quantum conference,” said Don Figer , director of RIT’s Future Photon Initiative. “For the past two years, this event has provided an important forum to discuss the latest breakthroughs in quantum science and technology, as well as how to unlock this growing field’s potential. We look forward to expanding the conference by accessing SPIE’s worldwide network.”
“We’re very excited to be partnering with RIT on this growing event,” said SPIE Director of Industry Development Stephen Anderson . “It’s a wonderful opportunity to help showcase the fast-emerging field of quantum technology and the exciting possibilities that exist in it for photonics. With its particular focus on scientific and academic content, covering both fundamental research and in-lab developments, Photonics for Quantum is a terrific complement to the industry-focused SPIE Quantum West and a great addition to the SPIE calendar.”
Registration for Photonics for Quantum is now open. Visit our website for more information and to register for the event .
About RIT
Rochester Institute of Technology is home to leading creators, entrepreneurs, innovators, and researchers. Founded in 1829, RIT enrolls 18,600 students in more than 200 career-oriented and professional programs, making it among the largest private universities in the US. The university is internationally recognized and ranked for academic leadership in business, computing, engineering, imaging science, liberal arts, sustainability, and fine and applied arts. RIT also offers unparalleled support services for deaf and hard-of-hearing students . The cooperative education program is one of the oldest and largest in the nation. Global partnerships include campuses in China, Croatia, Dubai, and Kosovo.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005138/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom